Gregory A. Dekaban1, Xizhong Zhang2, Vasiliki Economopoulos3, Jennifer Noad3, Roja Rohani3, Adele Wang4, Megan Levings4, Ronan Foley5, Paula Foster3
1BioTherapeutics Research Laboratory, Robarts Research Institute, London , Ontario, Canada; 2BioTherapeutics Research Laboratory, Robarts Research Institute, London, Ontario, Canada; 3Imaging Research Laboratories, Robarts Research Institute; 4Department of Surgery, University of British Columbia; 5Department of Pathology and Molecular Medicine, McMaster University
The successful migration of adequate numbers of in vitro-generated human dendritic cells (DC) from the site of injection to a draining lymph node is a necessary and crucial step in order for a DC-based vaccine to be a successful immunotherapy for cancer and infectious disease. Currently, less than 5% of injected DC migrate to a draining lymph node. How well a preparation of DC migrates is best assessed by conducting migration assays in vivo. Here we demonstrated that migration of human DC labeled with superparamagnetic iron oxide nanoparticles can be tracked to lymph nodes of CB17 scid mice.